DUBLIN--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the appointment of Gregory S. Andrulonis as Vice President and Treasurer, effective immediately.
Mr. Andrulonis succeeds Kevin G. DaSilva in this role. Mr. DaSilva will remain Vice President, Group Chief Financial Officer, responsible for finance activities in Covidien’s Respiratory & Monitoring Solutions and Vascular Therapies global business units, as well the Company’s businesses in Japan, Australia-New Zealand and Canada, a position he has held since July 2011. Mr. DaSilva served as treasurer of the Company since June 2007, when Covidien separated from Tyco International and became an independent company.
Mr. Andrulonis previously served as Vice President and Assistant Treasurer, Capital Planning and Markets, responsible for all aspects of Covidien's capital markets, capital planning and credit functions. This included equity and debt financing activities in the financial markets, capital planning and structure, interest rate and foreign exchange rate risk management, global credit and collections and retirement plan investments. He held this position since it was created in June 2007.
Prior to the separation, Mr. Andrulonis was the Director of Capital Markets for Tyco International. Prior to joining Tyco, he worked at Lucent Technologies as Regional Treasurer for Latin America, and he held several positions of increasing responsibility in treasury, credit and banking earlier in his career.
Mr. Andrulonis holds a bachelor’s degree from La Salle University and a master’s degree in finance from Temple University. Both universities are located in Philadelphia, Pennsylvania.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.